S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:GDRX

GoodRx - GDRX Stock Forecast, Price & News

$4.67
-0.14 (-2.91%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.66
$4.99
50-Day Range
$4.67
$7.81
52-Week Range
$4.66
$47.53
Volume
2.76 million shs
Average Volume
2.15 million shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.08

GoodRx MarketRank™ Forecast

Analyst Rating
Hold
2.24 Rating Score
Upside/​Downside
222.8% Upside
$15.08 Price Target
Short Interest
Healthy
17.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of GoodRx in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
300.00%
From $0.02 to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

246th out of 1,095 stocks

Data Processing & Preparation Industry

22nd out of 77 stocks

GDRX stock logo

About GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.

Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

GDRX Stock News Headlines

GoodRx (NASDAQ:GDRX) Hits New 52-Week Low at $5.56
GoodRx Stock Looks Ready to Be Priced Like a Generic Drug - RealMoney
GoodRx Stock Looks Ready to Be Priced Like a Generic Drug
Is it Now ‘Take Profit’ Time for GoodRx Holdings (GDRX)?
What 14 Analyst Ratings Have To Say About GoodRx Holdings
See More Headlines
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

GDRX Company Calendar

Last Earnings
8/08/2022
Today
10/02/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Data processing & preparation
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GDRX
Fax
N/A
Employees
756
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.08
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+222.8%
Consensus Rating
Hold
Rating Score (0-4)
2.24
Research Coverage
21 Analysts

Profitability

Net Income
$-25,250,000.00
Pretax Margin
1.34%

Debt

Sales & Book Value

Annual Sales
$745.42 million
Cash Flow
$0.11 per share
Book Value
$2.08 per share

Miscellaneous

Free Float
390,551,000
Market Cap
$1.85 billion
Optionable
Not Optionable
Beta
0.68

Key Executives

  • Mr. Douglas Joseph HirschMr. Douglas Joseph Hirsch (Age 51)
    Co-founder, Co-CEO & Director
    Comp: $927.77k
  • Mr. Trevor  BezdekMr. Trevor Bezdek (Age 44)
    Co-founder, Co-CEO, Sec. & Director
    Comp: $891.68k
  • Mr. Karsten Ian VoermannMr. Karsten Ian Voermann (Age 52)
    CFO & Principal Financial Officer
    Comp: $520.97k
  • Mr. Babak  AzadMr. Babak Azad (Age 48)
    Chief Marketing Officer and SVP of Marketing & Communications
    Comp: $500.4k
  • Mr. Bansi  NagjiMr. Bansi Nagji (Age 57)
    Pres of Healthcare
    Comp: $866.97k
  • Mr. Raj Beri
    Chief Operating Officer
  • Mr. Romin Nabiey (Age 35)
    Chief Accounting Officer & Principal Accounting Officer
  • Ms. Whitney Notaro
    VP of Investor Relations
  • Ms. Vina M. Leite (Age 52)
    Chief People Officer
  • Mr. Justin Fengler
    Sr. VP of Corp. Strategy & Bus. Operations













GDRX Stock - Frequently Asked Questions

Should I buy or sell GoodRx stock right now?

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 14 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings
or view top-rated stocks.

What is GoodRx's stock price forecast for 2022?

21 analysts have issued 1 year price objectives for GoodRx's shares. Their GDRX share price forecasts range from $6.00 to $47.00. On average, they predict the company's stock price to reach $15.08 in the next twelve months. This suggests a possible upside of 222.8% from the stock's current price.
View analysts price targets for GDRX
or view top-rated stocks among Wall Street analysts.

How have GDRX shares performed in 2022?

GoodRx's stock was trading at $32.68 at the start of the year. Since then, GDRX shares have decreased by 85.7% and is now trading at $4.67.
View the best growth stocks for 2022 here
.

When is GoodRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our GDRX earnings forecast
.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) released its quarterly earnings data on Monday, August, 8th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.04. The firm had revenue of $191.80 million for the quarter, compared to analyst estimates of $184.71 million. GoodRx had a negative net margin of 5.86% and a positive trailing twelve-month return on equity of 2.97%. The firm's revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.08 earnings per share.

What guidance has GoodRx issued on next quarter's earnings?

GoodRx issued an update on its third quarter 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $185.00 million-$185.00 million, compared to the consensus revenue estimate of $201.40 million.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

(GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

What is GoodRx's stock symbol?

GoodRx trades on the NASDAQ under the ticker symbol "GDRX."

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GoodRx's stock price today?

One share of GDRX stock can currently be purchased for approximately $4.67.

How much money does GoodRx make?

GoodRx (NASDAQ:GDRX) has a market capitalization of $1.85 billion and generates $745.42 million in revenue each year. The company earns $-25,250,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does GoodRx have?

The company employs 756 workers across the globe.

How can I contact GoodRx?

GoodRx's mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The official website for the company is www.goodrx.com. The company can be reached via phone at 855-268-2822 or via email at alex@blueshirtgroup.com.

This page (NASDAQ:GDRX) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.